Generics

MORRISTOWN, N.J. The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals, the drug maker said Tuesday.

Watson announced the FDA’s approval of Zarah (drospirenone and ethinyl estradiol tablets) in the 3 mg/0.03 mg strength. The drug is a generic version of Bayer’s Yasmin.

PITTSBURGH Generic drug maker Mylan has managed to snag Bioniche Pharma Holdings sooner than expected, Mylan said Tuesday. Mylan had announced its plans to buy Bioniche for $550 million in July.

PEAPACK, N.J. The generics subsidiary of Pfizer is launching a new business focused on authorized generics.

Greenstone announced Tuesday the launch of the Authorized Generics Alliance, which it said would combine its business model and 17 years of experience in the generics market with the expertise of other drug makers to market authorized generics in the United States under the Greenstone label.

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.

MORRISTOWN, N.J. The Food and Drug Administration has approved a generic drug made by Actavis for treating attention deficit hyperactivity disorder, Actavis said Wednesday.

The FDA approved the drug maker’s atomoxetine hydrochloride capsules in the 10-mg, 18-mg, 25-mg, 40-mg, 60-mg, 80-mg and 100-mg strengths. The drug is a generic version of Eli Lilly’s Strattera, which had $532 million in sales during the 12-month period ended in June, according to IMS Health.

NORTH WALES, Pa. Teva Pharmaceuticals has launched a generic treatment for epileptic seizures.

The world’s largest generic drug maker announced Wednesday the launch of diazepam rectal gel, a generic version of Valeant Pharmaceuticals’ Diastat AcuDial. The drug is administered via rectal syringe and is available in 2.5-mg, 10-mg and 20-mg strengths.

MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.

RALEIGH, N.C. Salix Pharmaceuticals announced its agreement with Novel Labs to settle its patent litigation over Novel’s proposed generic version of MoviPrep.